Journal of Clinical Oncology · 1999 · 199 citations · 21 references
MedicineHematologyOncologyCell TherapyKidney TransplantationStem Cell TransplantationAllogeneic Stem Cell TransplantationCellular TherapyDonor Lymphocyte InfusionImmunosuppression In Kidney TransplantationRenal Cell CarcinomaTransplant RejectionAllogeneic Stem Cell InfusionAllogeneic Stem Cell TherapyCyclophosphamide-based ConditioningGranulocyte Colony-stimulating Factor AdministrationGranulocyte Colony-stimulating Factor MobilizationHematopoietic ChimerismMetastatic Renal Cell Carcinoma TherapyPost-transplant Cyclophosphamide
PURPOSE: A 50-year-old man developed progressive pulmonary metastasis resistant to interferon alfa-2b treatment 7 months after he underwent left nephrectomy for stage III renal cell carcinoma. We performed a nonmyeloablative allogeneic peripheral-blood stem-cell transplant in this patient to exploit a possible graft-versus-tumor effect from allogeneic lymphocytes. MATERIALS AND METHODS: The conditioning regimen consisted of fludarabine and cyclophosphamide followed by a T-cell replete, granulocyte-colony stimulating-factor-mobilized peripheral-blood stem-cell transplant from his HLA-identical brother. Cyclosporine was administered from days -4 to +45 to prevent graft rejection and acute graft-versus-host disease (GVHD). RESULTS: Serial polymerase chain reaction analysis of hematopoietic lineage-specific minisatellites initiallyshowed mixed chimerism in CD14(+) and CD15(+) myeloid cells, CD3(+) T cells, and CD34(+) progenitor cells, with rapid conversion to 100% donor T-cell chimerism by day +60 and 100% donor myeloid cells by day +100. Serial computed tomography scans of the chest showed stable disease at day +30, slight regression of pulmonary lesions at day +63, and complete disappearance of all pulmonary metastatic disease by day +110. Mild transient acute GVHD disease of the skin occurred on day +60 and limited chronic GVHD of the skin occurred by day +200. CONCLUSION: The complete regression of metastatic disease, which has now been maintained for more than 1 year, is compatible with a graft-versus-tumor effect.
21
Graft-versus-leukemia reactions after bone marrow transplantation
MM Horowitz, Gale Rp, Sondel Pm et al. · Blood · 1990 · 2.8K citations · Full text
Medicine, Hematology, Immunology +11
Shimon Slavin, Arnon Nagler, E Naparstek et al. · Blood · 1998 · 1.9K citations · Full text
Medicine, Hematology, Oncology +17